Trastuzumab deruxtecan delivered at lower doses, is advised as a preferred second-line treatment option based on the results of the phase II DESTINY-Lung01 study, with a median OS of 17.8 months.333 Other data indicate that T-DM1 is also effective for patients with HER-2 mutation in metastatic or recurrent NSCLC, which is an active area of research at present. Here, ERBB2 is linked to non-small cell lung carcinoma.